MED31抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10243(MED31 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10243(MED31 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

The MED31 antibody targets the Mediator Complex Subunit 31 (MED31), a component of the multi-protein Mediator complex critical for regulating RNA polymerase II-driven transcription in eukaryotes. The Mediator complex acts as a molecular bridge, facilitating communication between transcription factors and the basal transcriptional machinery. MED31. a conserved subunit, plays roles in stabilizing the complex and modulating specific transcriptional programs, particularly those linked to metabolic regulation, stress responses, and developmental pathways.

MED31 antibodies are widely used in research to investigate gene expression mechanisms, protein-protein interactions, and MED31's involvement in diseases. For example, studies have implicated MED31 in cancers, metabolic disorders, and neurodegenerative conditions, where its dysregulation may alter transcriptional outputs. These antibodies enable techniques like Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and co-immunoprecipitation (Co-IP) to assess MED31 expression, localization, and binding partners.

Developed in hosts such as rabbits or mice, MED31 antibodies are validated for specificity and affinity, often through knockout controls or siRNA knockdown. Their application has advanced understanding of MED31's structural contributions to the Mediator complex and its functional interplay with nuclear receptors or other transcription factors. Ongoing research leverages these tools to explore therapeutic targeting of Mediator subunits in disease contexts.